Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes.
Tamara K Oser, Thomas Martens, Katrina J Ruedy et al.
✦ AI-curated · Sources linked
In 30 seconds
This 26-week, multicenter randomized trial compared continuous glucose monitoring (CGM) with routine care in adults with type 2 diabetes not using insulin at 22 US primary care practices. Among 283 participants, glycated hemoglobin fell from 8.8% to 7.2% with CGM and from 8.7% to 8.0% with routine care; the adjusted between-group difference was -0.9 percentage points (95% CI, -1.1 to -0.6; P<0.001). CGM also increased time in the 70 to 180 mg per deciliter glucose range, with no severe hypoglycemia events reported.
Key findings
- At 26 weeks, the adjusted glycated hemoglobin difference was -0.9 percentage points (95% CI, -1.1 to -0.6; P<0.001) favoring CGM.
- Time in the 70 to 180 mg per deciliter range was 21 percentage points higher (95% CI, 16 to 26) with CGM than routine care (P<0.001).
- Time below 70 mg per deciliter was lower with CGM by 0.20 percentage points; no severe hypoglycemia events were reported.
Why it matters
The trial provides randomized evidence that CGM can improve glycemic control and reduce hyperglycemia among adults with type 2 diabetes managed without insulin in primary care. These results extend evidence for CGM beyond insulin-treated populations and may inform discussions about glucose monitoring options, while the study’s duration and setting define the population to which its findings most directly apply.
What to keep in mind
Follow-up was limited to 26 weeks, and the trial was conducted in primary care practices in the United States.